CY1125690T1 - Αντιμυκητιασικα μεσα με ενισχυμενηδραστηριοτητα σε οξινο ρη - Google Patents

Αντιμυκητιασικα μεσα με ενισχυμενηδραστηριοτητα σε οξινο ρη

Info

Publication number
CY1125690T1
CY1125690T1 CY20221100767T CY221100767T CY1125690T1 CY 1125690 T1 CY1125690 T1 CY 1125690T1 CY 20221100767 T CY20221100767 T CY 20221100767T CY 221100767 T CY221100767 T CY 221100767T CY 1125690 T1 CY1125690 T1 CY 1125690T1
Authority
CY
Cyprus
Prior art keywords
conditions
acidic
enfumafungin
prevention
treatment
Prior art date
Application number
CY20221100767T
Other languages
Greek (el)
English (en)
Inventor
David A. ANGULO GONZALEZ
Original Assignee
Scynexis, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63209698&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1125690(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scynexis, Inc. filed Critical Scynexis, Inc.
Publication of CY1125690T1 publication Critical patent/CY1125690T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CY20221100767T 2017-08-04 2022-12-06 Αντιμυκητιασικα μεσα με ενισχυμενηδραστηριοτητα σε οξινο ρη CY1125690T1 (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762541370P 2017-08-04 2017-08-04

Publications (1)

Publication Number Publication Date
CY1125690T1 true CY1125690T1 (el) 2026-02-25

Family

ID=63209698

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20221100767T CY1125690T1 (el) 2017-08-04 2022-12-06 Αντιμυκητιασικα μεσα με ενισχυμενηδραστηριοτητα σε οξινο ρη

Country Status (26)

Country Link
US (3) US11534433B2 (https=)
EP (3) EP4732902A2 (https=)
JP (1) JP7214714B2 (https=)
KR (1) KR102807716B1 (https=)
CN (2) CN111093655A (https=)
AU (2) AU2018309718B2 (https=)
BR (1) BR112020002290A2 (https=)
CA (1) CA3071940A1 (https=)
CY (1) CY1125690T1 (https=)
DK (1) DK3661503T3 (https=)
EA (1) EA202090445A1 (https=)
ES (1) ES2932658T3 (https=)
FI (1) FI3661503T3 (https=)
HR (1) HRP20221414T1 (https=)
HU (1) HUE060508T2 (https=)
LT (1) LT3661503T (https=)
MA (1) MA49751B1 (https=)
MD (1) MD3661503T2 (https=)
MX (1) MX2020001399A (https=)
PL (1) PL3661503T3 (https=)
PT (1) PT3661503T (https=)
RS (1) RS63746B1 (https=)
SI (1) SI3661503T1 (https=)
SM (1) SMT202200461T1 (https=)
TW (1) TWI805600B (https=)
WO (1) WO2019028034A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA55081A (fr) * 2019-02-27 2022-01-05 Scynexis Inc <smallcaps/>? ? ?pneumocystis? ? ? ? ?antifongiques triterpénoïdes pour le traitement ou la prévention de la pneumonie àspp
BR112021022876A2 (pt) * 2019-05-16 2022-04-12 Scynexis Inc Método para descolonizar candida auris de uma área anatômica de um sujeito
WO2022140646A1 (en) * 2020-12-26 2022-06-30 Mycovia Pharmaceuticals, Inc Dosing regimen for oteseconazole

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756472A (en) 1996-01-31 1998-05-26 Merck & Co., Inc. Antifungal agent obtained from hormonema
DK2007396T3 (da) 2006-04-03 2013-03-18 Merck Sharp & Dohme Enfumafungin-derivat som antimykotika
RS53731B1 (sr) * 2008-08-12 2015-06-30 Scynexis, Inc. Antigljivični agensi
US8188085B2 (en) 2008-08-12 2012-05-29 Merck Sharp & Dohme Corp. Antifungal agents
LT3247711T (lt) 2015-01-19 2022-05-25 Scynexis, Inc. Naujos scy-078 druskos ir polimorfai
EP3609539A1 (en) * 2017-04-10 2020-02-19 Scynexis, Inc. Antifungal agents used in combination

Also Published As

Publication number Publication date
US20200390751A1 (en) 2020-12-17
CA3071940A1 (en) 2019-02-07
TW201919476A (zh) 2019-06-01
EP4169514B1 (en) 2026-01-28
HUE060508T2 (hu) 2023-03-28
MD3661503T2 (ro) 2023-01-31
CN111093655A (zh) 2020-05-01
SI3661503T1 (sl) 2023-01-31
AU2018309718A1 (en) 2020-02-27
ES2932658T3 (es) 2023-01-23
HRP20221414T1 (hr) 2023-01-20
SMT202200461T1 (it) 2023-01-13
EP4169514C0 (en) 2026-01-28
EP3661503B1 (en) 2022-09-07
EP3661503A1 (en) 2020-06-10
TWI805600B (zh) 2023-06-21
PL3661503T3 (pl) 2023-01-09
US11534433B2 (en) 2022-12-27
MA49751A (fr) 2020-06-10
MA49751B1 (fr) 2022-12-30
US20230364067A1 (en) 2023-11-16
CN118542868A (zh) 2024-08-27
LT3661503T (lt) 2022-12-12
EP4169514A1 (en) 2023-04-26
EP4732902A2 (en) 2026-04-29
WO2019028034A1 (en) 2019-02-07
RS63746B1 (sr) 2022-12-30
AU2018309718B2 (en) 2024-07-25
BR112020002290A2 (pt) 2020-09-08
MX2020001399A (es) 2020-08-06
US20260000656A1 (en) 2026-01-01
PT3661503T (pt) 2022-12-13
DK3661503T3 (da) 2022-12-12
JP2020529999A (ja) 2020-10-15
EA202090445A1 (ru) 2020-06-23
JP7214714B2 (ja) 2023-01-30
KR20200044823A (ko) 2020-04-29
FI3661503T3 (fi) 2022-12-15
AU2024227501A1 (en) 2024-11-07
KR102807716B1 (ko) 2025-05-13

Similar Documents

Publication Publication Date Title
CY1125690T1 (el) Αντιμυκητιασικα μεσα με ενισχυμενηδραστηριοτητα σε οξινο ρη
CY1124206T1 (el) Αναστολεις πυριδοπυριμδινονης cdk2/4/6
CY1125247T1 (el) Μεθοδοι θεραπειας καταθλιψης χρησιμοποιωντας ανταγωνιστες υποδοχεα ορεξινης-2
MX381041B (es) Compuesto cíclico tipo cumarina como inhibidor de mek y su uso.
CY1124810T1 (el) Συνδυαστικη θεραπεια για τη θεραπευτικη αντιμετωπιση του καρκινου
CY1122614T1 (el) 11-υδροξυλ-6-υποκατεστημενα-παραγωγα χολικων οξεων και συζευγματα αμινοξεων αυτων ως ρυθμιστες υποδοχεων χ φαρνεσοειδων
CY1122821T1 (el) Παραγωγα 1,3-βενζοδιοξολιου ως αναστολεις εζη1 ή/και εζη2
PH12017501326A1 (en) Tgf-� inhibitors
CY1125230T1 (el) Οξυστερολες και μεθοδοι χρησης αυτων
CY1121334T1 (el) Αναστολεας κινασης aurora a
EA202191051A1 (ru) Ингибитор аврора-киназы a для применения для лечения нейробластомы
JOP20210083B1 (ar) مترافقات عقار جسم مضاد تشتمل على مشتقات إكتيناسكيدين
JOP20200122B1 (ar) مركبات مفيدة لتثبيط cdk7
CY1123137T1 (el) Ιμιδαζο[1.2α]πυριδινες για αντιμετωπιση ή προληψη υπερουριχαιμιας ή ουρικης αρθριτιδας
MX391812B (es) Agonista fxr derivado de esteroides.
CY1126039T1 (el) Ενωσεις και συνθεσεις ουριας ως αναστολεις της ατρ-ασης smarca2/brm
BR112018074268A2 (pt) pastas dentais terapêuticas e métodos e kits relacionados
BR112015022551A2 (pt) inibidores de amido pirrol
JOP20190130A1 (ar) مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
CY1124643T1 (el) Νεα ενωση και φαρμακευτικα αποδεκτο αλας αυτης
BR112018074985A2 (pt) composições antibacterianas
EA201990765A1 (ru) Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок
MX379245B (es) Compuesto de tres ciclos y aplicaciones del mismo
CL2018001407A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer
MX2019006768A (es) Peptidos antimicrobianos.